MOMELOTINIB DOSE-INTENSITY IS MAINTAINED IN JAK INHIBITOR NAÏVE
AND PREVIOUSLY JAK INHIBITOR TREATED INTERMEDIATE/HIGH RISK
POSTER 10
MYELOFIBROSIS PATIENTS
Vikas Gupta1, Åsa Derolf2, Miklós Egyed3, Marek Hus4, Ilya Kirgner5, Ewa Lech-Maranda6, Jiri Mayer7,
Adam Mead8, Donal McLornan9, Zsolt Nagy10, Stephen Oh11, Uwe Platzbecker12, Jacek Treliński13, David
Ross14, Srdan Verstovsek15, Bianca Xicoy16, Sung-Soo Yoon17, Gregg Smith18, Mark Kowalski19 and Ruben
Mesa20
(1)Princess Margaret Cancer Centre, Toronto, Canada
(2)Department of Medicine, Division of Hematology, Karolinska University Hospital Solna, Karolinska
Institutet, Stockholm, Sweden
(3)Hematology Department of Somogy County, Teaching Hospital Mór Kaposi, Kaposvár, Hungary
(4)Department of Haematooncology and Bone Marrow Transplantation, Medical University, Lublin,
Poland
(5)Division of Hematology Sackler Faculty of Medicine Tel Aviv University, Tel Aviv, Israel,
(6)Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland
(7)Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic
(8)University of Oxford, Oxford, United Kingdom, (9)Guy's and Saint Thomas' NHS Foundation Trust,
London, United Kingdom
(10)1st Department of Internal Medicine, Semmelweis University, Budapest, Hungary
(11)Washington University School of Medicine, St. Louis
(12)Leipzig University Hospital, Leipzig, Germany
(13)Medical University of Lodz, Lodz, Poland
(14)University of South Australia and SA Pathology, Adelaide, Australia
(15)Department of Leukemia, MD Anderson Cancer Center, Houston, TX
(16)Institut Català d'Onoclogia-Hospital germans trias i Pujol, Barcelona, Spain
(17)Seoul National University Hospital, Seoul, Korea, Republic of (South)
(18)Sierra Oncology Ltd., Vancouver, Canada
(19)Sierra Oncology Inc., Vancouver, Canada
(20)UT Health San Antonio Cancer Center, San Antonio, TX
Momelotinib (MMB) is a potent JAK1, JAK2 and ACVR1 inhibitor with activity against each of
the three hallmark features of myelofibrosis (MF), anemia, constitutional symptoms and
splenomegaly, across the continuum of intermediate/high risk MF patients including JAKi-naïve
and previously JAKi-treated subjects. A retrospective analysis was conducted to
characterize dose intensity (DI) of MMB versus ruxolitinib (RUX) in the previously conducted
SIMPLIFY Phase 3 studies and to investigate MMB DI in patients switching from RUX.
Mean daily doses of MMB and RUX were calculated over the 24-week randomized treatment
(RT) periods in the Phase 3 SIMPLIFY-1 and -2 clinical trials (S1, S2). S1 was conducted in JAKi-naïve
MF patients (n=432) randomized 1:1 to MMB or RUX. S2 was conducted in prior RUX-treated
MF patients with hematological toxicity (n=156) randomized 2:1 to MMB or best
available therapy (BAT; 88% of which was RUX). Patients randomized to RUX or BAT were
eligible to cross-over to MMB at the end of RT and the MMB mean daily dose over the
subsequent 24-week open-label extended treatment (ET) periods was also calculated for both
studies.
SCIENTIFIC PROGRAMME
SESSION I
OPTIMIZING
CYTOREDUCTION
SESSION II
MANAGEMENT OF CML
WITH TKI
SESSION III
MPN RISK
STRATIFICATION
INCLUDING VASCULAR
EVENTS
DEBATE 1
INTERFERON ALPHA
SHOULD BE FRONT LINE
THERAPY IN ALL ET/PV
PATIENTS
ROUNDTABLE 1
INFECTIONS IN
MYELOPROLIFERATIVE
DISORDERS, INCLUDING
CML
ROUNDTABLE 2
PREGNANCY AND
PARENTING
DEBATE 2
ALLOGENEIC STEM CELL
TRANSPLANTATION
SHOULD BE CONSIDERED
THIRD LINE OPTION IN
CHRONIC PHASE CML
SESSION IV
EVOLVING THERAPIES
IN MYELOFIBROSIS
SESSION V
MANAGEMENT OF
ADVANCED AND UNUSUAL
DISEASE (MPN AND CML)
SESSION VI
TREATMENT FREE
REMISSION IN CML
KEYNOTE LECTURE
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
FO R A POSTER
PRESENTATION
DISCLOSURES